China Taiping Insurance
VC Fund
Hong Kong, Hong Kong
China Taiping Insurance is a VC fund in Hong Kong focused on Biotechnology and Medical. China Taiping Insurance Group Ltd. (“China Taiping”) is a Chinese state-owned financial and insurance group.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries China Taiping Insurance invests in
Stages China Taiping Insurance invests in
Countries China Taiping Insurance invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 4 (27%)
- Medical 3 (20%)
- Health Care 3 (20%)
- Medical Device 3 (20%)
- Internet 2 (13%)
Stage
- Series A 5 (33%)
- Series B 3 (20%)
- Series C 2 (13%)
- Funding Round 2 (13%)
- Venture - Series Unknown 2 (13%)
Country
- China 13 (87%)
- Japan 1 (7%)
- United States 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kenneth Ng
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aipuqiang
|
Shanghai Aipuqiang Particle Equipment is committed to providing customers with independently developed advanced proton therapy systems, based on independent innovation and with the mission of creating domestically produced high-end particle therapy technology to benefit cancer patients and contribute to the Healthy China strategy. | $142.7M / Series B / Dec 27, 2025 | |
Kanglin Biotech
|
Kanglin Biotech is a national high-tech company that create first- and best-in-class revolutionary gene therapies.Kanglin Biopharma specializes in the discovery, development, and commercialization of novel gene therapy treatments for diseases that adversely impair human health, including as thalassemia, AIDS, hemophilia, and Parkinson'sdisease. | Series A / Sep 15, 2025 | |
Shenzhen Energy Environmental Protection Co.
|
Shenzhen Energy Environmental Protection Co. is a waste disposal company providing research, engineering design, and operation management. | $691.7M / Mar 11, 2025 | |
METiS Pharmaceuticals
|
METiS Pharmaceuticals is the world's first AI-driven drug formulation company. | $100M / Series C / Jun 22, 2024 | |
Junjiu Electronics
|
Junjiu Electronics is a high tech enterprise that manufactures OEMs and automotive electronic parts, provides parts testing and consulting services, SOA architecture design and development, designs technical solutions and Controller software and hardware design, development and mass production. | $14.1M / Series A / May 30, 2023 | |
Immunochina
|
ImmunoChina Pharmaceuticals manufactures medical products. The Company produces cell injections, cell therapy drugs, and other products. ImmunoChina Pharmaceuticals also provides medical technology development, medical research, medical trial development, and other services. | Venture - Series Unknown / May 08, 2023 | |
Evaheart
|
Evaheart is a supplier of medical devices. They offer products that include a hydraulically levitated impeller, an open-vane impeller with large flow gaps, pump speed modulation, and a novel double-cuff tipless inflow cannula. | $90M / Series A / Mar 09, 2023 | |
|
Doma Biopharmaceutical
|
Doma Biopharmaceutical is a biotech company. | $142.1M / Series A / Jun 01, 2022 | |
Yingsheng Biology
|
Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. | Series C / Mar 29, 2022 | |
China Mobile
|
China Mobile provides mobile telecommunications and related services in Mainland China and Hong Kong.Its portfolio of services comprises of local calls, domestic long distance calls, international long distance calls, intra-provincial roaming, inter-provincial roaming, and international roaming, caller identity display, caller restrictions, callwaiting, call forwarding, call holding, voice mail, conference calls, and others.In addition, the company offers data services, wireless data traffic services, telecommunications network planning design and consulting services, mobile data solutions, network planning and optimizing construction testing and supervising activities, technology support, designing and selling electronic communication products, and more.It was incorporated in 1997 and is based in Central, Hong Kong. China Mobile Limited is a subsidiary of China Mobile Hong Kong (BVI) Limited. | $3.8B / Post-IPO Equity / Dec 28, 2021 | |
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does China Taiping Insurance invest in?
China Taiping Insurance invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact China Taiping Insurance?
Public channels for China Taiping Insurance include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at China Taiping Insurance?
The team at China Taiping Insurance includes Kenneth Ng (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
